Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 29, 2012 - Issue 4
Submit an article Journal homepage
182
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Genetic Polymorphism of γ-Glutamyl Hydrolase in Chinese Acute Leukemia Children and Identification of a Novel Double Nonsynonymous Mutation

Xiaowen ChenLaboratory of Molecular Hematology, Shenzhen Institute of Pediatrics, Shenzhen Children's Hospital, Shenzhen, People's Republic of China
, MMed,
Feiqiu WenLaboratory of Molecular Hematology, Shenzhen Institute of Pediatrics, Shenzhen Children's Hospital, Shenzhen, People's Republic of China
, MD,
Lijie YueCorrespondence[email protected]
, MD &
Changgang LiLaboratory of Molecular Hematology, Shenzhen Institute of Pediatrics, Shenzhen Children's Hospital, Shenzhen, People's Republic of China
, MB
Pages 303-312 | Received 09 Dec 2011, Accepted 11 Jan 2012, Published online: 08 May 2012

REFERENCES

  • Galivan J, Ryan TJ, Chave K, Glutamyl hydrolase: pharmacological role and enzymatic characterization. Pharmacol Ther. 2000;85:207–215.
  • Galivan J, Ryan T, Rhee M, Glutamyl hydrolase: properties and pharmacologic impact. Semin Oncol. 1999;26:33–37.
  • Koizumi S, Curt GA, Fine RL, Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest. 1985;75:1008–1014.
  • Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res. 1993;53:2227–2230.
  • Yao R, Rhee MS, Galivan J. Effects of gamma-glutamyl hydrolase on folyl and antifolylpolyglutamates in cultured H35 hepatoma cells. Mol Pharmacol. 1995;48:505–511.
  • Rumberger BG, Schmid FA, Otter GM, Sirotnak FM. Preferential selection during therapy in vivo by edatrexate compared to methotrexate of resistant L1210 cell variants with decreased folylpolyglutamate synthetase activity. Cancer Commun. 1990;2:305–310.
  • McCloskey DE, McGuire JJ, Russell CA, Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem. 1991;266:6181–6187.
  • Pizzorno G, Moroson BA, Cashmore AR, Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res. 1995;55:566–573.
  • Longo GS, Gorlick R, Tong WP, gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res. 1997;9:259–263.
  • Cheng Q, Wu B, Kager L, A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics. 2004;14:557–567.
  • Hayashi H, Fujimaki C, Inoue K, Genetic polymorphism of C452T (T127I) in human gamma-glutamyl hydrolase in a Japanese population. Biol Pharm Bull. 2007;30:839–841.
  • Chen X, Yue L, Li C, Li C. A novel G473A mutation in the glucose-6-phosphate dehydrogenase gene. Pediatr Blood Cancer. 2010;55:383–385.
  • Luo XQ, Ke ZY, Guan XQ, The comparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemia in China. Pediatr Blood Cancer. 2008; 51:204–209.
  • Chave KJ, Auger IE, Galivan J, Ryan TJ. Molecular modeling and site-directed mutagenesis define the catalytic motif in human gamma-glutamyl hydrolase. J Biol Chem. 2000;275:40365–40370.
  • Panetta JC, Wall A, Pui CH, Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin Cancer Res. 2002;8:2423–2429.
  • Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694–703.
  • Hayashi H, Fujimaki C, Daimon T, Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharmacol Ther. 2009;34:355–361.
  • Guldberg P, Guttler F. A simple method for identification of point mutations using denaturing gradient gel electrophoresis. Nucleic Acids Res. 1993;21:2261–2262.
  • van der Hout AH, van den Ouweland AM, van der Luijt RB, A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat. 2006;27:654–666.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.